GlassScriptPhysician profile
Mark H Harder
NPI 1093787459
$731.44
in general payments reported to CMS, 2019-2025
12 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.52 · 2020: $38.80 · 2021: $23.20 · 2022: $163 · 2023: $126 · 2024: $71.65 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $210.77 | 2022-2025 | Rocklatan, Hydrus Microstent |
| Amgen INC. | $136.50 | 2024-2025 | Tepezza |
| Glaukos Corporation | $101.16 | 2022-2025 | Istent Infinite, Idosetr |
| Mallinckrodt Hospital Products INC. | $72.12 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $54.39 | 2023 | Vyzulta |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Aerie Pharmaceuticals, INC. | $23.20 | 2021 | |
| Sun Pharmaceutical Industries INC. | $21.79 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.28 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $19.16 | 2023 | |
| Dompe US, INC. | $17.54 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $16.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.